The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 1st 2024
Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.
Dr. Choueiri on Synergy Between Immunotherapy and VEGF Inhibitors in RCC
July 26th 2017Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the synergy between immunotherapy agents and VEGF inhibitors in renal cell carcinoma (RCC).
Dr. Balar on Combinations with Pembrolizumab for Urothelial Cancer
July 21st 2017Arjun V. Balar, MD, assistant professor of Medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.
Dr. Apolo on the Safety of Nivolumab Plus Cabozantinib in Urothelial Carcinoma
July 19th 2017Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.
Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC
July 12th 2017Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).
Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer
July 11th 2017Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.
Future of Immunotherapy for GU Malignancies Goes Beyond Oncology Department
June 28th 2017Costas Lallas, MD, discusses the current role of immunotherapy for patients with genitourinary cancers, the potential for immunotherapy in combination with chemotherapy, and how the rise of immunotherapy affects all providers treating patients with these malignancies.